Pharma Mar S.A. Logo

Pharma Mar S.A.

Biopharmaceutical company developing oncology treatments from marine sources.

PHM | MC

Overview

Corporate Details

ISIN(s):
ES0169501022 (+1 more)
LEI:
959800QWKZ45ZQC2AV58
Country:
Spain
Address:
Avenida de los Reyes 1 Polígono Industrial La Mina, 28770 Colmenar Viejo

Description

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-28 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-24 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-10-08 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-09-22 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-19 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-18 00:00
Se informa que todas las propuestas de acuerdos presentadas por el Consejo a la…
Spanish 389.6 KB
2025-06-18 00:00
Se remite copia de la presentación a accionistas que será realizada en la Junta…
Spanish 2.5 MB
2025-06-09 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-09 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-06-05 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-26 17:41
La Sociedad informa de las operaciones llevadas a cabo al amparo del Programa d…
Spanish 171.3 KB
2025-05-23 00:00
Motivo de la notificación: Persona con Responsabilidad de Dirección
Spanish 91.4 KB
2025-05-22 00:00
Motivo de la notificación: Persona Estrechamente Vinculada
Spanish 91.4 KB
2025-05-21 08:27
La Sociedad presenta la solicitud en la UE para comercializar lurbinectedina en…
Spanish 744.9 KB

Automate Your Workflow. Get a real-time feed of all Pharma Mar S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharma Mar S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharma Mar S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.